What is Bachem?
Headquartered in Bubendorf, Switzerland, Bachem specializes in creating active pharmaceutical ingredients (APIs) for drug development and commercial manufacturing. The company is a trusted partner for both research-grade and commercial-scale production, offering comprehensive services from early-stage research and development through clinical trials to full-scale manufacturing. Bachem's expertise spans solid-phase and liquid-phase peptide synthesis, alongside advanced oligonucleotide manufacturing capabilities crucial for the burgeoning field of genetic medicines and RNA therapeutics. Operating state-of-the-art facilities globally, Bachem adheres to rigorous quality standards and regulatory compliance, catering to a diverse clientele from biotech startups to multinational pharmaceutical giants. Their work supports the advancement of therapeutics across oncology, metabolic disorders, cardiovascular diseases, and rare genetic conditions, positioning them as an essential component of the pharmaceutical supply chain.
How much funding has Bachem raised?
Bachem has raised a total of $633.7M across 1 funding round:
Share Placement
$633.7M
Share Placement (2021): $633.7M, investors not publicly disclosed
What's next for Bachem?
The recent major strategic investment signals Bachem's ongoing commitment to expanding its capabilities and market reach within the highly competitive pharmaceutical and biotechnology sectors. This capital infusion is expected to fuel further innovation in peptide and oligonucleotide technologies, potentially enabling the company to enhance its manufacturing capacity and accelerate the development of novel therapeutics. Bachem's strategic focus on supporting drug discovery and production, particularly in advanced areas like genetic medicines, suggests a trajectory aimed at solidifying its position as a key enabler of next-generation medicines and a critical partner for companies navigating the complex path from discovery to market.
See full Bachem company page
